Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Accumulated Expenses (2019 - 2022)

C4 Therapeutics (CCCC) has 4 years of Other Accumulated Expenses data on record, last reported at $309000.0 in Q1 2022.

  • For Q1 2022, Other Accumulated Expenses fell 65.16% year-over-year to $309000.0; the TTM value through Mar 2022 reached $309000.0, down 65.16%, while the annual FY2021 figure was $413000.0, 11.94% down from the prior year.
  • Other Accumulated Expenses reached $309000.0 in Q1 2022 per CCCC's latest filing, down from $413000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $887000.0 in Q1 2021 and bottomed at $164000.0 in Q3 2020.
  • Average Other Accumulated Expenses over 4 years is $370750.0, with a median of $294500.0 recorded in 2019.
  • Peak YoY movement for Other Accumulated Expenses: soared 67.5% in 2020, then plummeted 65.16% in 2022.
  • A 4-year view of Other Accumulated Expenses shows it stood at $280000.0 in 2019, then skyrocketed by 67.5% to $469000.0 in 2020, then decreased by 11.94% to $413000.0 in 2021, then fell by 25.18% to $309000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $309000.0 in Q1 2022, $413000.0 in Q4 2021, and $201000.0 in Q3 2021.